Abbreviations & Acronyms ADT = androgen deprivation therapy AR = androgen receptor AS = alternative splicing AVPC = aggressive variant prostate carcinoma CgA = chromogranin A CRPC = castration-resistant prostate cancer IHC = immunohistochemistry LCNEC = large cell neuroendocrine carcinoma NA = not available NE = neuroendocrine NEPC = neuroendocrine prostate cancer NSE = neuron-specific enolase OS = overall survival PCa = prostate adenocarcinoma PEG10 = paternally expressed 10 REST = RE1-silencing transcription factor SCC = small cell carcinoma SRRM4 = serine/arginine repetitive matrix 4 SYP = synaptophysin t-NEPC = treatment-related neuroendocrine prostate cancer TRAMP = transgenic adenocarcinoma mouse prostate Abstract: Treatment-related neuroendocrine prostate cancer is a lethal form of prostate cancer that emerges in the later stages of castration-resistant prostate cancer treatment. Treatment-related neuroendocrine prostate cancer transdifferentiates from adenocarcinoma as an adaptive response to androgen receptor pathway inhibition. The incidence of treatment-related neuroendocrine prostate cancer has been rising due to the increasing use of potent androgen receptor pathway inhibitors. Typically, treatmentrelated neuroendocrine prostate cancer is characterized by either low or absent androgen receptor expression, small cell carcinoma morphology and expression of neuroendocrine markers. Clinically, it manifests with predominantly visceral or lytic bone metastases, bulky tumor masses, low prostate-specific antigen levels or a short response duration to androgen deprivation therapy. Furthermore, although the tumor initially responds to platinum-based chemotherapy, the duration of the response is short. Based on the poor prognosis, it is imperative to identify novel molecular targets for treatmentrelated neuroendocrine prostate cancer. Recent advances in genomic and molecular research, supported by novel in vivo models, have identified some of the key molecular characteristics of treatment-related neuroendocrine prostate cancer. The gain of MYCN and AURKA oncogenes, along with the loss of tumor suppressor genes TP53 and RB1 are key genomic alterations associated with treatment-related neuroendocrine prostate cancer. Androgen receptor repressed genes, such as BRN2 and PEG10, are also necessary for treatment-related neuroendocrine prostate cancer. These genetic changes converge on pathways upregulating genes, such as SOX2 and EZH2, that facilitate lineage plasticity and neuroendocrine differentiation. As a result, on potent androgen receptor pathway inhibition, castration-resistant prostate cancer transdifferentiates to treatment-related neuroendocrine prostate cancer in a clonally divergent manner. Further understanding of the disease biology is required to develop novel drugs and biomarkers that would help treat this aggressive prostate cancer variant.
Introduction
PCa is the second most common malignancy among men worldwide. 1, 2 The standard treatment for metastatic PCa is ADT; 3 however, eventually cancer cells acquire resistance and CRPC develops. It is now widely accepted that the majority of CRPCs are still dependent on the AR signaling pathway, 4, 5 and novel AR pathway inhibitors, such as enzalutamide and abiraterone, have shown efficacy against CRPC. [6] [7] [8] [9] T-NEPC is a rare AR-independent cancer subtype that develops at the later stage of CRPC treatment. 10, 11 Morphologically, it shows features of small cell carcinoma, and typically has low or absent AR expression. 12 Clinically, it overlaps with "anaplastic prostate carcinoma" or "AVPC," which are characterized by extensive visceral metastases, short response duration to ADT, sensitivity to platinum-containing chemotherapy and poor prognosis. 13, 14 t-NEPC develops as a consequence of lineage plasticity, a phenomenon in which tumor cells acquire phenotypic characteristics of a cell lineage whose survival is no longer regulated by a certain drug target. 15 The incidence of t-NEPC has been rising rapidly as a result of the increasing use of potent AR pathway inhibitors, and it is now imperative to study the molecular characteristic of this aggressive subtype and identify specific molecular targets. Recent integrative genomic analysis and novel in vivo models of t-NEPC have identified several key molecular features of NEPC. In the present review, we discuss various clinical and molecular aspects of t-NEPC.
Definition and classification of NEPC
Until recently, there has been considerable debate regarding the definition and classification of NEPC, which has resulted in contradictory reports regarding its clinical significance. 12, 16 In 2013, the Prostate Cancer Foundation assembled a working committee to address this issue and proposed a new pathological classification of NEPC. 17 The new classification consisted of: (i) usual prostate adenocarcinoma with NE differentiation; (ii) adenocarcinoma with Paneth cell NE differentiation; (iii) carcinoid tumor; (iv) small cell carcinoma; (v) LCNEC; and (vi) mixed NE carcinoma-acinar adenocarcinoma. In addition, CRPC with a small cell carcinoma-like clinical presentation, which is often referred to as "t-NEPC," was also defined as an independent entity. "Anaplastic prostate carcinoma" 13 and "AVPC" 14 have also been used interchangeably to describe this specific disease state, although these are defined entirely based on clinical features, and might encompass a broader range of AR-independent CRPCs. 18 Histologically, NEPCs are characterized by positive IHC for NE markers, such as CgA, SYP and CD56 (NCAM). However, in clinical practice, routine IHC of prostate cancer for NE markers is not recommended, as the clinical impact of NEPC other than SCC and t-NEPC is unclear. 17 Hence, unless the tumor shows morphologically distinct SCC components, PCa mixed with NE marker-positive cells should be given standard hormone therapy (either with or without chemotherapy depending on the clinical context).
Clinical features of t-NEPC
The incidence of pure de novo SCC has been reported to be <2%. 19 However, the incidence of t-NEPC has been rapidly rising due to the increasing use of potent AR pathway inhibitors. A recent autopsy series showed that up to 25% of the patients dying from CRPC showed some signs of t-NEPC. 20 It is now recognized that t-NEPC arises as a result of lineage plasticity, whereby tumor cells transdifferentiate from AR-driven adenocarcinoma to t-NEPC, and escape from AR pathway inhibition. Therefore, with the ongoing development of more potent AR pathway inhibitors, the incidence of t-NEPC is expected to increase further. 14 De novo SCC and t-NEPC share both an aggressive phenotype and poor prognosis. The key clinical features of t-NEPC are exclusively visceral or predominantly lytic bone metastases, bulky tumor masses, low prostate-specific antigen levels relative to tumor burden or short response duration to ADT. 13 In a literature review of 123 t-NEPC patients, the time to development of t-NEPC from initial diagnosis of PCa was 20 months, and the median survival after t-NEPC was just 7 months. 21 Among the cases included, 56.3% showed pure SCC histology, and 36.9% showed mixed adenocarcinoma and SCC histology. The duration of ADT before transdifferentiation was <24 months in more than half of the patients. In a multivariate analysis, a high Gleason score (≥8) was associated with a shorter time to t-NEPC. Similar to lung SCC, which is known to cause a paraneoplastic syndrome, Cushing's syndrome was reported in nine cases, although the relatively high incidence might be due to reporting bias.
The first-line chemotherapy for PCa is docetaxel; 22 however, in either SCC or t-NEPC, a platinum-based regimen similar to the treatment of lung SCC has been widely used. The most commonly used regimen is cisplatin or carboplatin combined with etoposide. A phase II study from France (GETUG-P01) assessed the efficacy and toxicity of carboplatin (area under curve 4) and etoposide (100 mg/m 2 , days 1-3) regimen for the patients meeting the criteria of anaplastic prostate cancer with or without serum NE marker (NSE, CgA) elevation. 23 The objective response rate was just 8.9%, and the median OS was 9.6 months. The authors concluded that the benefit-to-risk ratio of the regimen was unfavorable. Another phase II study administered first-line carboplatin and docetaxel, and secondline etoposide and cisplatin to 120 anaplastic prostate cancer patients. 13 Although a complete or partial response was observed in nearly one-third of the patients after at least two cycles of treatment, the duration of the response was short, and the median OS was 16 months. The results of phase II clinical trials for the currently available chemotherapeutic regimen and potential novel therapeutics under development are summarized in Table 1 . 13, [23] [24] [25] Notice that the patient selection criteria varies between the studies, and the data cannot be compared directly. Based on these studies and the results of chemotherapy for SCC of the lung, NCCN guideline recommends a combination of etoposide with either cisplatin or carboplatin, or docetaxel in combination with carboplatin, or clinical trial for cases with SCC histology. Whether platinum-based chemotherapy has an advantage over taxanes in the "anaplastic" cases without SCC histology remains to be elucidated.
Cellular origin of t-NEPC
The normal prostate gland contains NE cells randomly distributed among the basal and luminal cells. 17 These cells secrete various peptide hormones, including CgA, calcitonin and NSE, and affect the surrounding epithelial cells in a paracrine manner. However, in the normal prostate gland, these NE cells are quiescent. Whether NEPC arises either by transformation and clonal selection of pre-existing NE cells in the prostate gland or from transdifferentiation of adenocarcinoma cells has been controversial. 26, 27 However, mounting evidence supports that t-NEPC transdifferentiates from an adenocarcinoma as a consequence of epithelial plasticity. 14, [28] [29] [30] [31] TMPRSS-ERG translocation is observed in nearly half of the PCa cases in Western countries, 32 and is one of the driver events in PCa carcinogenesis. 33 The reported frequency of the translocation is similar in t-NEPC compared with that in adenocarcinoma; 34 and in the cases of mixed NEPC adenocarcinoma, there was perfect concordance with regard to the translocation status between NEPC and adenocarcinoma foci. 19 In addition, there was a substantial overlap in the somatic copy number landscape between CRPC and t-NEPC. 31 Recent genomic studies have found MYCN amplification in 40% of t-NEPCs. 19 Enforced expression of MYCN and AKT1 in basal epithelial cells from benign prostate tissue was sufficient to generate a mixed adenocarcinoma and NEPC, showing that both adenocarcinoma and NEPC can arise from a common epithelial clone. 35 These genetic and molecular studies support transdifferentiation rather than clonal selection for the formation of t-NEPC. However, data are still lacking with regard to the origin of de novo SCC.
Research models of t-NEPC
Research on NEPC has been lagging significantly due to the lack of suitable in vitro and in vivo models. However, the recent increase in t-NEPC prevalence has prompted the generation of several novel in vivo models.
LNCaP cells have long been used as a NEPC transdifferentiation model. It is widely known that LNCaP cells start to show neuronal cell-like morphology and express NE markers when exposed to various treatments (androgen deprivation, 36 ). Some studies have shown that these cells might promote the growth of surrounding cells in a paracrine manner. 44 However, these "neuron-like" cells are morphologically distinct from SCC and generally show decreased growth, 45 unlike clinically aggressive t-NEPC. It is likely that these cells represent the quiescent NE cells seen in some CRPC specimens and do not influence the clinical outcome. Emerging evidence suggests that additional genetic aberrations, including TP53 mutation and RB1 loss, provide a genomic context with increased proliferation and outgrowth of transdifferentiated neuroendocrine cells for emergence of t-NEPC. 28, 30, 31, [46] [47] [48] NCI-H660 is the only existing cell line that was derived from clinical NEPC biopsy. The cell line was originally described as a lung SCC; 49 however, it was later determined to be derived from the prostate. It harbors the TP53 mutation and RB1 deletion, as well as the TMPRSS-ERG fusion. 50 Interestingly, the cell line grows as floating cells similar to most other small cell carcinoma cell lines from the lung, and grows much faster in vivo compared with its growth in vitro. It is possible that interaction with the proper microenvironment is important for rapid growth of NEPC. LTL-331/LTL-331R is a novel patient-derived xenograft model of t-NEPC. 29 The model was established by grafting a Gleason score 9 adenocarcinoma from a patient into the mouse subrenal capsule. The tumor (LTL-331), which initially expresses AR and prostate-specific antigen, regresses on castration, and later re-grows rapidly without elevation of serum prostate-specific antigen. The re-grown tumor (LTL-331R) shows SCC morphology, does not express either AR or prostate-specific antigen, and expresses neuronal markers, including CgA and SYP. Even though LTL-331 and LTL-331R show a very similar copy number profile and fusion gene profile, LTL-331R is highly similar to the clinical t-NEPC tumor at the transcriptome level. Interestingly, the LTL-331 harbors a single-copy loss of TP53 and a functional C277G mutation in the remaining allele. 28 In addition, there is a single-copy loss of RB1, and on transdifferentiation to LTL-331R, a significant alteration in the Rb pathway gene signature is observed, compatible with genetic changes typically seen in t-NEPC. It is possible that these genomic alterations of TP53 and RB1 predispose the model to NEPC transdifferentiation. Several other patient-derived xenografts for NEPC have been reported; [51] [52] [53] however, to date, the LTL-331 model is the only existing model of transdifferentiation.
MYCN, in cooperation with either PTEN loss or AKT1 overexpression, is known to drive NEPC development in a murine model. 54 As MYCN and AURKA overexpression/amplification is one of the most common genetic events found in clinical NEPC, this model is optimal to study the key molecular mechanisms of NEPC development, and also serves as a model for testing therapeutics. Another murine model of NEPC involves a conditional double knockout of TP53 and RB1 in the prostate. 48 The genetic signature of the double knockout model was similar to that of clinical NEPC, and showed increased expression of SOX2 and EZH2, two key epigenetic reprogramming genes important in generating induced pluripotent stem cells. SOX2 and EZH2 are both implicated in NEPC development, and might play a key role in driving epithelial plasticity.
The TRAMP is a mouse model with prostate-specific expression of SV40 large T antigen. 55 TP53 and RB1 are inactivated specifically in the prostate due to the expression of SV40 large T antigen. The TRAMP male mouse develops PCa with distant metastases by 24-30 weeks-of-age, and subsequently progresses to NEPC. As the TP53 mutation and Rb1 loss are key genetic aberrations of prostate and lung SCC, TRAMP is a convenient model to study the natural progression to NEPC. There are also cell lines derived from TRAMP for in vitro use. 56 Genomic and molecular characteristics of t-NEPC MYCN and AURKA amplification Next-generation sequencing technology identified some of the key genomic alterations and molecular pathways critical for t-NEPC development. RNA sequencing and oligonucleotide array of a cohort of NEPC and PCa clinical samples followed by validation using a large patient cohort showed MYCN and AURKA overexpression/gene amplification in 40% of NEPC and 5% of PCa samples. 19 Beside its role in mitosis, Aurora kinase A is known to interact with and stabilize N-myc. 57 Both AURKA and MYCN are oncogenes, and interestingly, in nearly all AURKA amplification-positive cases of NEPC, there was concurrent amplification of MYCN. 19, 58 Furthermore, Aurora kinase A and N-myc cooperatively induce the NEPC phenotype in prostate cells in vivo and in vitro. NCI-H660 xenografts, which express a high level of N-myc, were sensitive to an Aurora kinase A inhibitor in vivo, in contrast to no sensitivity in LNCaP xenografts with low N-myc expression. The finding has led to an ongoing phase II clinical trial using the Auroka kinase A inhibitor, MLN8237 (Alisertib), in t-NEPC patients (ClinicalTrials.gov Identifier: NCT01799278). The finding has also led to establishment of the previously mentioned murine models expressing MYCN. 54 Prostate-specific overexpression of MYCN, in cooperation with PTEN knockout, resulted in an aggressive carcinoma with a variety of morphologies, including foci of AR-positive adenocarcinoma, poorly differentiated carcinoma with divergent differentiation and an AR-negative NEPC tumor. Interestingly, tumors later developed liver metastases of NEPC origin. Gene set enrichment analysis showed enrichment of PRC2/EZH2 targets and suppression of AR signaling. EZH2, a component of the PRC2 complex that primarily methylates H3K27 to suppress transcription, is significantly overexpressed in clinical NEPC compared with that in PCa. 19, 31 It was shown that Nmyc and EZH2 form a complex with the AR to suppress AR signaling. 54 In addition, EZH2 cooperatively suppresses expression of other N-myc repressed genes, which results in driving the NEPC molecular program. The critical role of Nmyc in driving NEPC has also been supported by a study that showed that deregulated expression of MYCN and AKT1 in primary human prostate epithelial cells produced tumors with mixed NEPC and adenocarcinoma components. 35 
p53 and Rb pathway aberrations
Another key feature of NEPC is aberrant p53 and Rb signaling pathways, which is also observed in lung SCC. 59, 60 This was first shown by IHC followed by copy number analysis of prostate SCC and PCa. 61 The study showed Rb protein loss in 90% of SCCs, with RB1 allelic loss in 85% of the cases. Accumulation of p53 was observed in 56% of SCCs with 60% of the cases showing a TP53 mutation. Another study similarly showed RB1 copy number loss to be the strongest discriminator between "aggressive variant prostate cancer" and unselected CRPC. 46 As RB1 copy number analysis is not feasible in a clinical pathology lab, and functional loss of Rb is not detectable by IHC, IHC for p16 overexpression and cyclin D1 loss was tested as a surrogate marker for NEPC. 62 Cyclin D1 is a cell-cycle regulator whose expression and function are controlled by the Rb pathway. The expression of cyclin D1 as detected by IHC paralleled the loss of the Rb signature, and overall, 88% of SCCs showed cyclin D1 loss compared with <10% in high-grade PCa, indicating cyclin D1 IHC is a feasible method to identify prostate tumors with NE differentiation.
Recently, two studies have identified the functional relationship between the dysregulated p53 and the Rb pathways in t-NEPC development. The first study showed in vitro that dual knockdown or knockout of TP53 and RB1 promoted lineage plasticity evidenced by increased expression of basal and neuroendocrine markers, and reduced expression of luminal cell markers. 47 In addition, knockdown of both TP53 and RB1 was sufficient to confer enzalutamide resistance. The effect of TP53 and RB1 knockdown on lineage plasticity and growth was likely mediated by SOX2. The second study showed in vivo that RB1 loss promotes lineage plasticity of adenocarcinoma initiated by PTEN loss, and that additional loss of TP53 confers resistance to ADT. 48 The increased lineage plasticity was likely conferred by increased expression of SOX2 and EZH2. Even though a direct relationship between MYCN/AURKA amplification and p53/Rb pathway dysregulation has not been clarified yet, aberrations of these major oncogenes or tumor suppressor genes converge on the same pathway through SOX2 and EZH2 to increase lineage plasticity.
The SIAH2-FOXA2 axis is another possible pathway driving t-NEPC in tumors with aberrant TP53 and RB1 levels.
63
SIAH2 is a ubiquitin ligase that regulates hypoxia inducible factor-1a availability. SIAH2 knockout in the TRAMP mouse model inhibited NEPC development by blocking the interaction between hypoxia inducible factor-1a and FoxA2, a transcription factor overexpressed in t-NEPC.
AR inhibition and t-NEPC development
There are a number of studies showing the functional impact of AR pathway inhibition on t-NEPC development. Using a unique panel of enzalutamide-resistant cell lines derived from serial in vivo selection of LNCaP xenografts, neural transcription factor BRN2 was identified as an androgen receptor-suppressed driver of t-NEPC. 64 BRN2 was directly repressed by AR; and in enzalutamide-resistant cells, BRN2 expression induced NE marker expression and promoted cell growth. Furthermore, it was shown that BRN2 regulates expression and activity of SOX2 in t-NEPC development.
PEG10 is another gene directly repressed by AR that is implicated in promoting the aggressive phenotype of t-NEPC. 28 PEG10 expression is elevated on castration, and further significantly upregulated at the final stage of t-NEPC transdifferentiation as a result of direct transcriptional upregulation by E2F1, a major transcription factor in the Rb signaling pathway. PEG10 is a retrotransposon-derived gene that retains gag and pol domains. 65 Similar to the HIV virus, it has a unique -1 ribosomal frameshift sequence that enables balanced expression of gag (RF1) and pol (RF1/2) proteins.
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PEG10 is a placental gene that is indispensable for mammalian placental development.
67 PEG10 RF1 promotes cell invasion through the transforming growth factor-b signaling pathway, and PEG10 RF1/2 promotes cell cycle progression in the absence of TP53 and RB1. In cells with wild-type TP53, PEG10 RF1/2 strongly induces p53 and p21 expression, in line with its role as a potent oncogene.
AS has also been implicated in the development of t-NEPC. In a study using whole transcriptome sequence data of adenocarcinoma and NEPC cohorts, 24 NEPC-specific AS events were identified.
68 SRRM4, an RNA splicing factor that was one of the most significantly upregulated genes in the clinical NEPC cohorts, was involved in 16 of the NEPCspecific AS events. Before the study, REST had been identified as a master repressor of NE markers in prostate cancer.
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SRRM4 induced AS of REST to decrease REST, and induced the expression of REST4, a splice variant that has lost the property to suppress NE marker expression. Furthermore, AS of REST and NE marker induction by SRRM4 were enhanced by AR pathway inhibition and TP53 loss, suggesting an important role of SRRM4 in driving transdifferentiation.
Clonal evolution of t-NEPC
Recently, the clonal evolution pattern of t-NEPC was studied by analyzing the whole-exome sequencing data of metastatic lesions biopsied from CRPC patients. 31 The study showed substantial genomic overlap between CRPC and t-NEPC. The analysis of sequential biopsies from the same patients during treatment suggested divergent clonal evolution, whereby both CRPC and t-NEPC cells could arise from the same CRPC clone in a divergent manner. Additionally, a recent report from SU2C/PCF/AACR West Coast Prostate Cancer Dream Team, which analyzed the whole transcriptome of biopsies from metastatic lesions, showed the presence of a distinct histology, intermediate to SCC and adenocarcinoma, which also supported divergent clonal expansion as a result of lineage plasticity. 18 Taken together, t-NEPC seems to arise from CRPC cells in response to AR pathway inhibition, and additional aberrations in the major oncogenes and tumor suppressor genes. These genetic aberrations result in overexpression of SOX2 and EZH2, which facilitate lineage plasticity and divergent differentiation to t-NEPC (Fig. 1) .
Novel therapeutic targets and biomarkers for t-NEPC
Currently, alisertib, an Aurora kinase A inhibitor, is the only molecular targeting agent being tested in a clinical trial. A multicenter phase II trial enrolling 59 patients (ClinicalTrials.gov Identifier: NCT01799278) showed a modest response; however, two patients achieved an exceptional response with complete resolution of liver metastases. A companion diagnostics to identify good responders is required.
EZH2 inhibitors also warrant further development. EZH2 silencing, as well as EZH2 inhibition using GSK503, restored the enzalutamide sensitivity of PTEN and RB1 double knockout mouse in vivo. 48 Another EZH2 inhibitor (GSK343) preferentially decreased the viability of NCI-H660 cells, as compared with that in other non-neuroendocrine prostate cancer cells.
Even though tumor suppressors, such as p53 and Rb, are not readily targetable, PEG10 is a common downstream effector that might be suitable for drug targeting. PEG10 is a placental gene whose expression in normal cells is restricted to embryonal organs and to neurons. 69 Furthermore, it has a unique -1 ribosomal frameshift sequence and also a protease domain similar to the HIV virus, which are potentially targetable. Novel biomarkers are also required, as common neuronal markers, including CgA, SYP, NCAM1 and NSE, are not sufficient to discriminate between clinically relevant aggressive small cell-like cancers from quiescent cancers with mixed NE histology. With a deeper understanding of the genomic landscape of t-NEPC, liquid biopsies might hold promise as a novel biomarker. 70 
Conclusions
With the increasing use of potent AR axis inhibitors, t-NEPC is emerging as a serious problem in prostate cancer treatment. The recent advances in both genomic and molecular studies have led to a deeper understanding of how t-NEPC arises from prostate adenocarcinoma. Novel in vivo models are now available to elucidate the molecular mechanisms and also to serve as models for testing therapeutics. It is expected that further understanding of disease biology would lead to the development of novel drugs and biomarkers that could help to eliminate this very aggressive cancer.
